Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986500 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Part 1A Monotherapy Dose Escalation | EXPERIMENTAL | - |
| Part 1B Combination Dose Escalation | EXPERIMENTAL | - |
| Part 1C Monotherapy Pharmacodynamic (PD) Sub-study | EXPERIMENTAL | - |
| Part 2A Monotherapy Dose Expansion | EXPERIMENTAL | - |
| Part 2B Combination Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986500 | DRUG | Specified dose of specified days |
| Palbociclib | DRUG | Specified dose on specified days |
| Fulvestrant | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must be ≥ 18 years of age. * Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy. * Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986500 is an investigational small molecule being developed for the treatment of advanced solid tumors, including advanced breast cancer and advanced ovarian cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
BMS-986500 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
BMS-986500 is in Phase 1 clinical development. It is being studied as a monotherapy or in combination therapy for advanced solid tumors. The drug is investigational and has not received approval from the U.S. Food and Drug Administration or other regulatory bodies.
BMS-986500 is being evaluated in a Phase 1 clinical trial with the identifier NCT06997029. This trial is recruiting participants with advanced solid tumors, including advanced breast cancer and advanced ovarian cancer, and is being conducted in the United States, Denmark, and Japan.
BMS-986500 is a distinct investigational drug candidate developed by Bristol-Myers Squibb. It is not known to be the same as any other approved or marketed medication. Its unique chemical structure and mechanism of action are under investigation in clinical trials.